GLP1R and Parkinson disease: Therefore, we propose to perform a systematic review and meta-analysis of randomized controlled clinical trials and preclinical studies evaluating the efficacy and safety of GLP-1 and GIP receptor agonists in slowing the progression of PD, exploring their potential mechanisms of neuroprotection.